Drug – bio-affecting and body treating compositions – Extract – body fluid – or cellular material of undetermined... – Blood
Reexamination Certificate
2011-01-11
2011-01-11
Saucier, Sandra (Department: 1651)
Drug, bio-affecting and body treating compositions
Extract, body fluid, or cellular material of undetermined...
Blood
C514S012200
Reexamination Certificate
active
07867519
ABSTRACT:
A method for modifying the properties of a fibrin matrix relative to growth and ingrowth of cells, wherein for forming the fibrin matrix a fibrinogen is used consisting of a selected fibrinogen variant or a fibrinogen enriched or depleted in a selected fibrinogen variant. In particular, the use of high-molecular weight (HMW) fibrinogen leads to a fibrin having accelerated angiogenesis properties, while the use of low-molecular weight (LMW and/or LMW′) fibrinogen leads to fibrin having decelerated angiogenesis properties. The use of HMW fibrinogen when setting up angiogenesis tests results in that the tests require less time. Fibrin sealants on the basis of HMW fibrinogen can be used for burns, to promote wound healing or to inhibit scar tissue. Fibrin sealants on the basis of LMW or LMW′ fibrinogen are useful to inhibit adhesions and tumor growth, for instance after surgical operations.
REFERENCES:
patent: 6946140 (2005-09-01), Clark et al.
patent: 1 142 581 (1991-11-01), None
patent: 98 55140 (1998-12-01), None
patent: 00/62833 (2000-10-01), None
patent: 00 72852 (2000-12-01), None
Gunji et al., “Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells”, Cancer Research 48 (18 ) : 5216-5221 (1988).
Vaage et al., “Normal inhibition of mammary tumor metastasis in C3H-He mice”, Clinical and Experimental Metastasis 9 (3) : 273-282 (1991).
Atagi et al., “Inhibition by fibrin coagulation of lung cancer cell destruction by human interleukin-2-activated killer cells”, Japanese Journal of Cancer Research 83 (10) : 1088-1094 (1992).
Holm et al., :Purification and characterization of 3 fibrinogens with different molecular weights obtained from normal human plasma, Thrombosis Research 37 : 165-176 (1985).
Hasegawa et al., “Location of the Binding Site “b” for Lateral Polymerization of Fibrin”, Thrombosis Research 57 : 183-187 (1990).
Smith et al., “The Role of Putative Fibrinogen A alpha-, B beta-, and gammaA-chain Integrin Binding Sites in Endothelial Cell-mediated Clot Retraction”, Journal of Biological Chemistry 272 (35) : 22080-22085 (1997).
Falls et al., “Resistance of gamma A/gamma” Fibrin Clots to Fibrinolysis, Journal of Biological Chemistry 272 (22) : 14251-14256 (1997).
Kaijzel et al., “Molecular weight fibrinogen variants determine antiogenesis rate in a fibrin matrix in vitro and in vivo”, J. Thrombosis and Haemostasis 4 : 1975-1981 (2006).
Zhang et al., “Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy”, Progress in Retinal and Eye Research 26 : 1-37 (2007).
Hallemeesch, Marcella M., et al.: “The turnover rate of HMW fibrinogen to LMW fibrinogen determines the plasma profile of these proteins”; FASEB Journal, Mar. 22, 2002 (ISSN 0892-6638); XP-002226013 © BIOSIS / BIOSIS.
Collen, Annemie, et al.: “Aberrant fibrin formation and cross-linking of fibrinogen Nieuwegein, a variant with a shortened Alpha-chain, alters endothelial capillary tube formation”, Blood, Feb. 15, 2001, vol. 97, No. 4; XP-002226021; © by the American Society of Hematology (pp. 973-980).
de Maat Monica Petronella Maria
Koolwijk Pieter
Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk On
Norris McLaughlin & Marcus P.A.
Saucier Sandra
LandOfFree
Method for the acceleration or deceleration of angiogenesis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the acceleration or deceleration of angiogenesis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the acceleration or deceleration of angiogenesis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2631612